drugset / Trial / NCT03473574
Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
To determine the efficacy in terms of objective response rate (ORR) of the combination of durvalumab and tremelimumab in addition with gemcitabine or in addition with gemcitabine and cisplatin in treatment-naïve patients with advanced, unresectable and/or metastatic cholangio- and gallbladder carcinoma (CCA).
Timeline
- Start
- 2018-05-02
- Primary completion
- 2022-03-15
- Completion
- 2022-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Durvalumab | Monoclonal antibody | — | — |
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Tremelimumab | Monoclonal antibody | — | — |